Sabra Healthcare REIT Inc (SBRA) Beta Value: Understanding the Market Risk

QCOM

The price-to-earnings ratio for Sabra Healthcare REIT Inc (NASDAQ: SBRA) is above average at 83.61x. The 36-month beta value for SBRA is also noteworthy at 1.24. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 7 rating it as “hold,” and 1 rating it as “sell.”

The public float for SBRA is 230.43M, and at present, short sellers hold a 8.20% of that float. The average trading volume of SBRA on October 23, 2024 was 2.17M shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

SBRA) stock’s latest price update

Sabra Healthcare REIT Inc (NASDAQ: SBRA) has seen a rise in its stock price by 0.43 in relation to its previous close of 18.59. However, the company has experienced a 2.47% gain in its stock price over the last five trading sessions. businesswire.com reported 2024-10-21 that TUSTIN, Calif.–(BUSINESS WIRE)– #Moodys–Sabra Health Care REIT, Inc. (“Sabra”) (Nasdaq: SBRA) announced today that Moody’s Ratings (“Moody’s”) issued a report on October 17, 2024 affirming Sabra’s Ba1 ratings and upgrading Sabra’s outlook to “Positive” from “Stable”. The report credits Sabra’s upgraded outlook to improving industry fundamentals for skilled nursing and senior housing, which is driving an improvement in Sabra’s key credit metrics, particularly net debt to EBITDA. For additional informat.

SBRA’s Market Performance

Sabra Healthcare REIT Inc (SBRA) has seen a 2.47% rise in stock performance for the week, with a -2.76% decline in the past month and a 12.54% surge in the past quarter. The volatility ratio for the week is 1.77%, and the volatility levels for the past 30 days are at 1.81% for SBRA. The simple moving average for the past 20 days is 1.98% for SBRA’s stock, with a 22.03% simple moving average for the past 200 days.

Analysts’ Opinion of SBRA

Many brokerage firms have already submitted their reports for SBRA stocks, with Wells Fargo repeating the rating for SBRA by listing it as a “Overweight.” The predicted price for SBRA in the upcoming period, according to Wells Fargo is $20 based on the research report published on October 01, 2024 of the current year 2024.

Citigroup, on the other hand, stated in their research note that they expect to see SBRA reach a price target of $20, previously predicting the price at $17. The rating they have provided for SBRA stocks is “Buy” according to the report published on September 13th, 2024.

Deutsche Bank gave a rating of “Buy” to SBRA, setting the target price at $21 in the report published on January 30th of the current year.

SBRA Trading at 5.20% from the 50-Day Moving Average

After a stumble in the market that brought SBRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.36% of loss for the given period.

Volatility was left at 1.81%, however, over the last 30 days, the volatility rate increased by 1.77%, as shares sank -1.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.54% upper at present.

During the last 5 trading sessions, SBRA rose by +2.47%, which changed the moving average for the period of 200-days by +36.88% in comparison to the 20-day moving average, which settled at $18.31. In addition, Sabra Healthcare REIT Inc saw 30.83% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at SBRA starting from Cusack Catherine, who purchase 7,000 shares at the price of $14.43 back on May 22 ’24. After this action, Cusack Catherine now owns 46,385 shares of Sabra Healthcare REIT Inc, valued at $101,010 using the latest closing price.

FOSTER MICHAEL J, the Director of Sabra Healthcare REIT Inc, sale 10,000 shares at $14.68 during a trade that took place back on May 14 ’24, which means that FOSTER MICHAEL J is holding 63,923 shares at $146,830 based on the most recent closing price.

Stock Fundamentals for SBRA

Current profitability levels for the company are sitting at:

  • 0.52 for the present operating margin
  • 0.51 for the gross margin

The net margin for Sabra Healthcare REIT Inc stands at 0.08. The total capital return value is set at 0.07. Equity return is now at value 1.83, with 0.96 for asset returns.

Based on Sabra Healthcare REIT Inc (SBRA), the company’s capital structure generated 0.47 points at debt to capital in total, while cash flow to debt ratio is standing at 0.12. The debt to equity ratio resting at 0.89. The interest coverage ratio of the stock is 2.7.

Currently, EBITDA for the company is 418.15 million with net debt to EBITDA at 5.65. When we switch over and look at the enterprise to sales, we see a ratio of 10.06. The receivables turnover for the company is 1.28for trailing twelve months and the total asset turnover is 0.13.

Conclusion

In summary, Sabra Healthcare REIT Inc (SBRA) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.

Related Posts